Prospective Study of Cellular & Clinical Aspects of Mod-Severe Asthma
Research type
Research Study
Full title
Prospective Study of Cellular and Clinical Aspects of Moderate to Severe Asthma
IRAS ID
254003
Contact name
Andrew Menzies-Gow
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
Asthma is the most common chronic respiratory disease and in many countries prevalence continues to rise. Although currently available medications effectively treat the majority of asthma patients, a substantial proportion of patients exist who remain difficult-to-treat. These patients account for a relatively large proportion of asthma hospitalisation and resource expenditure. Much remains unclear regarding the management of difficult-to-treat patients, or concerning the underlying mechanisms driving this processes.
The aim of this research study is to prospectively study a group of moderate to severe asthmatics to validate a panel of published biomarkers and to discover novel candidate biomarkers. These biomarkers could potentially allow us to distinguish patient sub-groups or disease severity. As such, this is an enabling study which will provide robust biomarkers (including proteins, RNA and clinical physiological and imaging markers) which can be used in the clinical development of novel therapeutic interventions and will provide further insight into the natural history of asthma and the pathogenesis of acute exacerbations.
REC name
London - Bloomsbury Research Ethics Committee
REC reference
19/LO/1675
Date of REC Opinion
23 Dec 2019
REC opinion
Further Information Favourable Opinion